FDA warned soma4ever.com for selling unapproved and misbranded opioids, benzodiazepines, and stimulants to U.S. consumers online.
What happened
FDA reviewed the website www.soma4ever.com and found it offered opioids, benzodiazepines, and Schedule II stimulants for sale to U.S. consumers. FDA said the site offered versions of tapentadol, oxycodone, tramadol, alprazolam, clonazepam, diazepam, lorazepam, and amphetamine without FDA-approved applications. FDA also said the site offered prescription drugs without requiring a prescription.
What FDA found
FDA says the website sells prescription drugs that are not FDA-approved for sale in the U.S., including opioids, benzodiazepines, and a Schedule II stimulant.
FD&C Act sections 301(d) and 505(a) [21 U.S.C. §§ 331(d), 355(a)]FDA says the drug labels do not give adequate directions for safe use by a layperson, which makes the drugs misbranded.
FD&C Act section 502(f)(1) [21 U.S.C. § 352(f)(1)]; section 301(a) [21 U.S.C. § 331(a)]FDA says the website offers prescription drugs for sale without a prescription, which misbrands the drugs.
FD&C Act section 503(b)(1) [21 U.S.C. § 353(b)(1)]; section 301(k) [21 U.S.C. § 331(k)]
What FDA wants
FDA asks the company to stop offering unapproved and misbranded drugs to U.S. consumers and to notify FDA in writing within 15 working days of steps taken to address the violations and prevent recurrence.
Who should pay attention
- online pharmacies and drug sellers
- marketers and websites linking to overseas pharmacies
- brand owners whose drug names appear on unapproved products
This is a summary. Read the original letter on fda.gov.